Structure-based identification of an inducer of the low-pH conformational change in the influenza virus hemagglutinin: irreversible inhibition of infectivity

Past efforts to employ a structure-based approach to design an inhibitor of the fusion-inducing conformational change in the influenza virus hemagglutinin (HA) yielded a family of small benzoquinones and hydroquinones. The most potent of these, tert-butyl hydroquinone (TBHQ), inhibits both the conformational change in HA from strain X:31 influenza virus and viral infectivity in tissue culture cells with 50% inhibitory concentrations in the micromolar range (D. L. Bodian, R. B. Yamasaki, R. L. Buswell, J. F. Stearns, J. M. White, and I. D. Kuntz, Biochemistry 32:2967-2978, 1993). A new structure-based inhibitor design search was begun which involved (i) the recently refined crystal structure (2.1-A resolution) of the HA ectodomain, (ii) new insights into the conformational change, and (iii) improvements in the molecular docking program, DOCK. As a result, we identified new inhibitors of HA-mediated membrane fusion. Like TBHQ, most of these molecules inhibit the conformational change. One of the new compounds, however, facilitates rather than inhibits the HA conformational change. Nonetheless, the facilitator, diiodofluorescein, inhibits HA-mediated membrane fusion and, irreversibly, infectivity. We further characterized the effects of inhibitors from both searches on the conformational change and membrane fusion activity of HA as well as on viral infectivity. We also isolated and characterized several mutants resistant to each class of inhibitor. The implications of our results for HA-mediated membrane fusion, anti-influenza virus therapy, and structure-based inhibitor design are discussed.

[1]  J. Skehel.  The origin of pandemic influenza viruses. , 1974 .

[2]  D. Wiley,et al.  Fusion mutants of the influenza virus hemagglutinin glycoprotein , 1985, Cell.

[3]  M. Krystal,et al.  Characterization of a hemagglutinin-specific inhibitor of influenza A virus. , 1996, Virology.

[4]  G. Semenza,et al.  Evidence for H(+)-induced insertion of influenza hemagglutinin HA2 N-terminal segment into viral membrane. , 1994, The Journal of biological chemistry.

[5]  A. Herrmann,et al.  Kinetics of the low pH-induced conformational changes and fusogenic activity of influenza hemagglutinin. , 1994, Biophysical journal.

[6]  R. Bethell,et al.  The kinetics of the acid-induced conformational change of influenza virus haemagglutinin can be followed using 1,1'-bis(4-anilino-5-naphthalenesulphonic acid). , 1995, Biochemical and biophysical research communications.

[7]  R F Service.  Researchers Seek New Weapon Against the Flu , 1997, Science.

[8]  J. Young,et al.  A soluble form of a receptor for subgroup A avian leukosis and sarcoma viruses (ALSV-A) blocks infection and binds directly to ALSV-A , 1994, Journal of virology.

[9]  J. White,et al.  GPI-anchored influenza hemagglutinin induces hemifusion to both red blood cell and planar bilayer membranes , 1995, The Journal of cell biology.

[10]  T. Wolfsberg,et al.  Virus-cell and cell-cell fusion. , 1996, Annual review of cell and developmental biology.

[11]  J. Tomassini,et al.  A novel antiviral agent which inhibits the endonuclease of influenza viruses , 1996, Antimicrobial agents and chemotherapy.

[12]  I. Kuntz,et al.  Automated docking with grid‐based energy evaluation , 1992 .

[13]  Brian K. Shoichet,et al.  Molecular docking using shape descriptors , 1992 .

[14]  Conrad C. Huang,et al.  The MIDAS display system , 1988 .

[15]  D. M. Ryan,et al.  4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro , 1993, Antimicrobial Agents and Chemotherapy.

[16]  N. Cox,et al.  Amantadine-resistant influenza A in nursing homes. Identification of a resistant virus prior to drug use. , 1995, Archives of internal medicine.

[17]  I. Wilson,et al.  Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution , 1981, Nature.

[18]  Keith Dudley.  Short protocols in molecular biology , 1990 .

[19]  D. Lambert,et al.  Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Skehel,et al.  Refinement of the influenza virus hemagglutinin by simulated annealing. , 1991, Journal of molecular biology.

[21]  S. Watowich,et al.  Crystal structures of influenza virus hemagglutinin in complex with high-affinity receptor analogs. , 1994, Structure.

[22]  T. Shangguan,et al.  Influenza-virus-liposome lipid mixing is leaky and largely insensitive to the material properties of the target membrane. , 1996, Biochemistry.

[23]  I. Kuntz,et al.  Protein docking and complementarity. , 1991, Journal of molecular biology.

[24]  J. White.  15 Fusion of Influenza Virus in Endosomes: Role of the Hemagglutinin , 1994 .

[25]  J. Skehel,et al.  Electron microscopy of antibody complexes of influenza virus haemagglutinin in the fusion pH conformation. , 1995, The EMBO journal.

[26]  Daniel A. Gschwend,et al.  Orientational sampling and rigid-body minimization in molecular docking revisited: On-the-fly optimization and degeneracy removal , 1996, J. Comput. Aided Mol. Des..

[27]  I. Wilson,et al.  Intermonomer disulfide bonds impair the fusion activity of influenza virus hemagglutinin , 1992, Journal of virology.

[28]  R. Lamb,et al.  Characterization of inhibition of M2 ion channel activity by BL-1743, an inhibitor of influenza A virus , 1996, Journal of virology.

[29]  T. F. Smith,et al.  Replication and plaque assay of influenza virus in an established line of canine kidney cells. , 1968, Applied microbiology.

[30]  J. Skehel,et al.  Structure of influenza haemagglutinin at the pH of membrane fusion , 1994, Nature.

[31]  D. Baker,et al.  Influenza hemagglutinin: kinetic control of protein function. , 1994, Structure.

[32]  J. Skehel,et al.  Role of virion M2 protein in influenza virus uncoating: specific reduction in the rate of membrane fusion between virus and liposomes by amantadine. , 1994, The Journal of general virology.

[33]  J. Glenn,et al.  Delivery of macromolecules into cells expressing a viral membrane fusion protein. , 1989, Methods in cell biology.

[34]  I. Kuntz,et al.  Using shape complementarity as an initial screen in designing ligands for a receptor binding site of known three-dimensional structure. , 1988, Journal of medicinal chemistry.

[35]  J. Henneberry,et al.  Variant influenza virus hemagglutinin that induces fusion at elevated pH , 1986, Journal of virology.

[36]  J. Skehel,et al.  Amantadine selection of a mutant influenza virus containing an acid-stable hemagglutinin glycoprotein: evidence for virus-specific regulation of the pH of glycoprotein transport vesicles. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Skehel,et al.  The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. , 1987, Annual review of biochemistry.

[38]  L. Hernandez,et al.  Receptor-induced conformational changes in the subgroup A avian leukosis and sarcoma virus envelope glycoprotein , 1995, Journal of virology.

[39]  I. Wilson,et al.  Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[40]  I D Kuntz,et al.  Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. , 1993, Biochemistry.

[41]  G. Air,et al.  Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. , 1995, Virology.

[42]  J. Skehel,et al.  Introduction of intersubunit disulfide bonds in the membrane-distal region of the influenza hemagglutinin abolishes membrane fusion activity , 1992, Cell.

[43]  H. Morselt,et al.  Fusion of influenza virus in an intracellular acidic compartment measured by fluorescence dequenching. , 1987, Biochimica et biophysica acta.

[44]  G J Williams,et al.  The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1978, Archives of biochemistry and biophysics.

[45]  N. Cox,et al.  Genetic and antigenic analyses of influenza A (H1N1) viruses, 1986-1991. , 1993, Virus research.

[46]  F. Booy,et al.  Effects of low pH on influenza virus. Activation and inactivation of the membrane fusion capacity of the hemagglutinin. , 1987, The Journal of biological chemistry.

[47]  P. S. Kim,et al.  A spring-loaded mechanism for the conformational change of influenza hemagglutinin , 1993, Cell.

[48]  T. Matthews,et al.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[49]  H. Klenk,et al.  Influenza viruses cause hemolysis and fusion of cells. , 1981, Virology.

[50]  Judith M. White,et al.  Lipid-anchored influenza hemagglutinin promotes hemifusion, not complete fusion , 1994, Cell.

[51]  J. Skehel,et al.  The structure of a membrane fusion mutant of the influenza virus haemagglutinin. , 1990, The EMBO journal.

[52]  I. Wilson,et al.  Anti-peptide antibodies detect steps in a protein conformational change: low-pH activation of the influenza virus hemagglutinin , 1987, The Journal of cell biology.

[53]  M. Nahata,et al.  Rimantadine: A Clinical Perspective , 1995, The Annals of pharmacotherapy.